Authors
Anna Azvolinsky
Latest:
FDA Grants Crizotinib Priority Review in ROS1-Mutated Lung CancerThe targeted, oral therapy crizotinib (Xalkori), has been granted priority review by the US Food and Drug Administration (FDA) for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) who have c-ros oncogene 1 (ROS1)-rearranged tumors.
Carl Regillo, MD
Latest:
Intravitreal Gene Therapy for Wet AMDAn overview of new gene therapy options for wet AMD that are currently being explored in clinical trials.
